(Reuters) - A combination of five oral drugs being tested by AbbVie Inc cured at least 88 percent of new patients with hepatitis C after only eight weeks of treatment, ...
Read more
April 23, 2013 6:04 am by Berkrot, Bill | 0 Comments
(Reuters) - A combination of three experimental Bristol-Myers Squibb hepatitis C drugs appeared to be highly effective, according to data from a mid-stage clinical trial, keeping the company in the ...
Read more
Vertex Pharmaceuticals Inc. said today it has entered into a non-exclusive agreement with Bristol-Myers Squibb Company to conduct second, all-oral studies of the former's VX-135 drug with the latter's drug, ...
Read more
February 23, 2013 1:27 pm by Lee, Mara | 0 Comments
Three months after Achillion Pharmaceuticals Inc. said it had enough cash to operate through the middle of 2014, it has decided to issue another $125 million worth of stock.The shares ...
Read more
(Reuters) - Gilead Sciences Inc said a late-stage trial testing its experimental hepatitis C drug showed no detectable virus level in 73 percent of study patients after 16 weeks of ...
Read more
Preventing, identifying and treating infectious diseases has been a hot spot for innovation in healthcare. This growing company, though, is taking a step back, focusing instead on improving the process ...
Read more
The technician was indicated Wednesday in New Hampshire on 14 new charges. The outbreak involved more than 30 patients in New Hampshire while people in a number of other states ...
Read more
Nov 19 (Reuters) - GlaxoSmithKline Plc said U.S. health regulators had approved its drug Promacta for the additional use of treating hepatitis C patients with a low platelet count who ...
Read more
(Reuters) - A trio of oral medicines from Abbott Laboratories Inc to treat hepatitis C produced unprecedented cure rates in patients who had previously failed to benefit from standard treatment, ...
Read more
November 10, 2012 10:00 am by Clarke, Toni | 0 Comments
BOSTON (Reuters) - Boehringer Ingelheim said on Saturday it plans to initiate a late-stage clinical trial of its experimental hepatitis C treatment following promising results from earlier studies.The company announced ...
Read more
(Reuters) - An all oral regimen of hepatitis C medicines developed by Abbott Laboratories led to high cure rates in both new patients and those for whom prior treatment failed, ...
Read more
(Reuters) - Achillion Pharmaceuticals Inc said an early-stage trial of its experimental hepatitis C treatment showed that a single dose of the drug significantly reduced the severity of the infection.The ...
Read more
Sept 25 (Reuters) - Vertex Pharmaceuticals Inc said on Tuesday it will discontinue development of an experimental drug to treat hepatitis C after it failed to show sufficient efficacy to ...
Read more
A clinical-stage biopharmaceutical company developing drug candidates for hepatitis D and hepatitis C has secured $4.6 million of its targeted $5 million funding round. ...
Read more
(Reuters) - Bristol-Myers Squibb Co has discontinued development of an experimental hepatitis C drug after a patient treated with the drug in a clinical trial died of heart failure and ...
Read more
